US-based clinical diagnostics company Bio-Techne has signed an agreement to acquire local firm Exosome Diagnostics for a total consideration of approximately $575m.

Under the terms of the deal, Bio-Techne will pay $250m in cash, followed by up to $325m of contingent consideration upon reaching select milestones in the future.

The strategic acquisition, which is scheduled to close in July or August this year, is expected to complement Bio-Techne’s molecular pathology business Advanced Cellular Diagnostics (ACD).

“Under the terms of the deal, Bio-Techne will pay $250m in cash, followed by up to $325m of contingent consideration upon reaching select milestones in the future.”

Exosome Diagnostics’ portfolio comprises a non-invasive urine test called ExoDx Prostate(IntelliScore) (EPI) designed to identify the requirement for prostate biopsy in patients whose PSA test result is not clear. The test is performed on exosomes isolated from urine.

Bio-Techne president and CEO Charles Kummeth said: “ExosomeDx’s technology is a game changer, and positions Bio-Techne to be a leader in the rapidly-growing non-invasive liquid biopsy market.

“This is a very strategic acquisition for us as we also expand in the CAR-T cell marketplace, leveraging our growing critical mass in cell culture-focused product lines.”

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

Bio-Techne plans to utilise its existing position to apply its core competencies to understand exosomes and cell free-DNA (cfDNA) biology and their use as diagnostic tools.

Exosome Diagnostics CEO John Boyce said: “We believe we have found the perfect partner to take our technology to the next level. Both companies share the vision to develop innovative tools that can revolutionise medicine and provide better care for patients.”

Exosome intends to leverage the concept of its exosome- and cfDNA-based analysis technology to develop diagnostics for other cancers.